Welcome to our dedicated page for Adaptimmune Therapeutics news (Ticker: ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics stock.
Adaptimmune Therapeutics plc reports corporate and business developments for its ADSs and engineered T-cell therapy operations in solid tumor cancers. News has covered financial results, TECELRA commercial updates, cell therapy asset transactions, debt repayment, restructuring activity, and remaining programs directed at PRAME and CD70.
Company updates also address Nasdaq listing matters, ADS trading status, deregistration actions, executive changes, and conference participation. Adaptimmune’s disclosed business context centers on its engineered T-cell receptor platform, personalized cell therapies, and the corporate transition following the completed transfer of TECELRA, lete-cel, afami-cel, and uza-cel assets.
Adaptimmune and Galapagos have entered a clinical collaboration to evaluate Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer. The trial aims to leverage Galapagos' decentralized manufacturing platform to improve efficacy and durability. Initial trials showed an 80% response rate with partial responses in four out of five patients. Adaptimmune will receive $70M upfront, $30M in R&D funding, and potentially up to $465M in milestone payments, with additional tiered royalties. Galapagos has an option to license uza-cel for global development and commercialization.
Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 2024 results, highlighting a cash runway through late 2025. Revenue fell to $5.7M from $47.6M YoY due to the termination of the Astellas collaboration. Net loss was $48.5M, compared to a $1.0M profit in Q1 2023. R&D expenses rose to $35.2M, driven by increased employee costs and lease properties from the TCR2 acquisition. G&A expenses decreased to $19.7M due to restructuring and lower corporate costs. The FDA is reviewing afami-cel for advanced synovial sarcoma with a PDUFA date of August 4, 2024. The company plans to launch afami-cel upon approval and lete-cel for synovial sarcoma and MRCLS in 2026, targeting peak U.S. sales of $400M. A $125M debt facility with Hercules Capital was secured.
Adaptimmune has secured a $125 million debt financing deal with Hercules Capital. The agreement includes an initial $25 million tranche available upon closing and an additional $25 million contingent on the approval of afami-cel. The remaining $75 million will be available subject to certain conditions. This financing aims to bolster the company's balance sheet as it prepares for the commercial launch of afami-cel later this year and lete-cel in 2026. Adaptimmune's CFO, Gavin Wood, expressed confidence in the potential impact of afami-cel on sarcoma treatment. A live webcast will provide further Q1 financial and business updates.
Adaptimmune Therapeutics plc (NASDAQ: ADAP) will report Q1 2024 financial results and business updates on May 15, 2024. The company specializes in solid tumor cancer treatment using cell therapy. A live webcast will follow the announcement at 8:00 a.m. EDT (1:00 p.m. BST) on the same day.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.